Few of the individuals who experience an opioid-related overdose had received treatment for opioid use disorder.
Mental health, education level, and recent drug use may be associated with duration of treatment with extended-release naltrexone for opioid dependence.
Euphoria associated with the stimulant methylphenidate may be mitigated by co-administration of naltrexone in patients with attention-deficit/hyperactivity disorder.
A longer duration of extended-release naltrexone treatment in individuals with opioid dependence was associated with improved outcomes and reduced rates of relapse.
All 3 opioid-dependence pharmacotherapies — methadone, buprenorphine, and oral naltrexone — were associated with reductions in inpatient substance abuse treatment.
Compared with buprenorphine-naloxone, use of extended-release naltrexone maintained abstinence from heroin and other illicit substances at a similar rate.
Early pharmacologic intervention for opioid use disorder after diagnosis is crucial to prevent relapse and overdose in adolescents and young adults.
Policies have helped make naloxone more available, thus contributing to the reduction of opioid-related deaths in the U.S.
An 8-day detoxification process using low-dose oral naltrexone showed superior efficacy to the standard 15-day approach that uses an agonist taper leading to induction with extended-release naltrexone
Clinical Pain Advisor Articles
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Half of Patients Referred for Behavioral Treatment of Migraine Never Initiate Treatment
- Emergency Physicians Offer Recommendations for Identifying and Managing Opioid Use Disorder
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness